Aims. The aim of this study was to determine the impact of the severity of anaemia on postoperative complications following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Methods. A retrospective cohort study was conducted using the American College of Surgeons National Quality Improvement Program (ACS-NSQIP) database. All patients who underwent primary TKA or THA between January 2012 and December 2017 were identified and stratified based upon hematocrit level. In this analysis, we defined anaemia as packed cell volume (Hct) < 36% for women and < 39% for men, and further stratified anaemia as mild anaemia (Hct 33% to 36% for women, Hct 33% to 39% for men), and moderate to severe (Hct < 33% for both men and women). Univariate and multivariate analyses were used to evaluate the incidence of multiple adverse events within 30 days of arthroplasty. Results. Following adjustment, patients in the THA cohort with moderate to severe anaemia had an increased odds of 6.194 (95% confidence interval (CI) 5.679 to 6.756; p < 0.001) for developing any postoperative complication. Following adjustment, patients in the TKA cohort with moderate to severe anaemia had an increased odds of 5.186 (95% CI 4.811 to 5.590; p < 0.001) for developing any postoperative complication. Among both cohorts, as severity increased, there was an increased risk of postoperative complications. Conclusion. Preoperative anaemia is a risk factor for complications following primary arthroplasty. There is a significant relationship between the severity of anaemia and the odds of postoperative complications. Patients who had moderate to severe anaemia were at increased risk of developing postoperative complications relative to patients with mild anaemia. When considering elective primary THA or TKA in a moderately or severely anaemic patient, surgeons should strongly consider correcting anaemia prior to surgery if possible. Cite this article: Bone Joint J 2020;102-B(4):485–494

Background. While tranexamic acid (TXA) has been well shown to reduce blood loss after joint replacement surgery, little is known regarding its effectiveness in obese patients. The aim of this study was to evaluate the effect of TXA changes in hematocrit and hemoglobin levels as well as incidence of packed red blood cell (pRBC) transfusions in obese patients undergoing total joint arthroplasty (TJA). Material and Methods. Between January 2014 and May 2015, 420 consecutive primary joint replacements were performed by two surgeons at our institution. 157 patients (THA=29; TKA=128) were obese with a body mass index (BMI) greater than or equal to 30 kg/m. 2. Medical records were reviewed and identified that TXA was utilized in 85 (54.1%) arthroplasties [study group] and was compared to a consecutive series of 72 (45.9%) TJAs [control group]. TXA was given intravenously(IV) in two doses: (1) one gram prior to incision and (2) one gram at the time of femoral preparation in THA or prior to cementation in TKA. Changes in hemoglobin and hematocrit levels, number of pRBC transfusions, and occurrence of thrombolytic events were recorded. Results. The changes in hematocrit (7.2% vs. 8.1%) and hemoglobin levels (3.0 g/dl vs. 3.3 g/dl) were less for group that received TXA than the control group, albeit not significantly (p=0.100 and p=0.278, respectively). Within the control group 26 (36.1%) patients required a pRBC transfusion with a mean of 2.0 units per patient (range:1–5); whereas, only 8 (9.4%) patients with TXA required a mean of 1.6 units per patient (range:1–2 units). The use of TXA significantly reduced the incidence of pRBC transfusions, especially in TKA (p<0.001). Sub-analyses revealed that transfusion rates were even more significantly reduced by TXA in obesity type II and III. Two pulmonary emboli were reported in the group that did not receive TXA, whereas no thrombolytic events were reported in the group that did receive TXA. Conclusion. Utilization of TXA significantly reduced the rate of pRBC transfusions in obese patients

Objectives. Tranexamic acid (TXA), an inhibitor of fibrinolysis blocking the lysine-binding site of plasminogen to fibrin, has been reported to reduce intraoperative and postoperative blood loss in patients undergoing primary total hip arthroplasty (PTHA) both with and without cement. Both intravenous (IV) and topical (TOP) administration of TXA can effectively reduce blood loss in THA without increasing risk of deep venous thrombosis (DVT). However, there have been few reports investigating the combination of intravenous and topical administration of TXA in bilateral cementless PTHA. We investigated the effects of combined intravenous and topical administration of TXA on postoperative blood loss, drainage volume, and perioperative complications in patients with bilateral simultaneous cementless PTHA for hip osteoarthritis. Patients and methods. We retrospectively reviewed the demographic and clinical data of 41 patients who underwent bilateral simultaneous cementless PTHA for hip osteoarthritis from May 2015 to January 2017, of which there were 29 male (70.7%) and 12 female (29.3%) patients. Patients in IV group (n= 11) received only TXA (15 mg/kg) 10 min prior to the incision of each side; and patients in IV + TOP group (n=13) received i.v. TXA (15 mg/kg) combined with topical adiministration (1.0 g) of TXA during the each THA procedure; patients in control group (n=17) received the same dosage of normal saline both i.v. and topically. Outcome measures were total blood loss, hemoglobin, hematocrit value (HCT) changes preoperatively, and on the 1st, 3rd postoperative day, the amount of drainage, and perioperative complications. Results. On the 1st, 3rd postoperative day, patients in group IV and group IV + TOP had significantly higher haematological parameters (haemoglobin, hematocrit value (HCT)) than patients in control group (P < 0.05 (group IV vs control group), P < 0.01 (group IV + TOP vs control group), respectively), while no significant differences found between patients in group IV and group IV + TOP (P > 0.05). The postoperative drainage volume of patients in group IV and group IV + TOP were significantly less than those in control group (P < 0.01, P < 0.01, respectively), while no significant differences found between those in group IV and group IV + TOP (P > 0.05). No significant differences were found in the perioperative complications (DVT or PE) among all three groups. Conclusion. The combined administration of intravenous and topical TXA resulted in a significantly reduction in postoperative blood loss, compared with placebo group. No adverse perioperative complications were observed. This study supports the combined intravenous and topical administration of TXA in bilateral cementless PTHA

An outpatient total hip arthroplasty (THA) will be defined as a THA performed at an ambulatory care facility where the patient is discharged the same day as the procedure. Such procedures are being done in the United States and the hypothesis is that a “same day” THA will lead to reduced costs and improved outcomes. However, there are no appropriately powered randomised controlled trials evaluating outcomes in this group of patients to support this hypothesis. It appears that a “same day” THA is here to stay. Therefore, the selection criteria for patients that undergo the procedure needs to be carefully defined. The safety of this regimen needs to be confirmed. In an evaluation of the NSQIP database, Otero et al. compared outcomes in patients discharged on POD 0 and POD 1 and noted that THA patients in the POD 0 group had increased rates of complications. Risk factors for complications included age >70, smoking, COPD, CAD and hematocrit less than 36. In addition, the patients discharged on POD 0 had higher rates of diabetes, steroid use and lower hematocrit. Clearly, the selection criteria for this procedure needs to be defined. In two separate studies, Goyal et al. and Dorr et al. noted that approximately 25% of patients were unable to leave the hospital on POD 0 usually because of nausea and/or hypertension. Issues to consider before developing a same day discharge program include: 1) Is the patient healthy enough to go home the same day as the surgery?; 2) Does the patient live close enough to the hospital to be discharged the same day?; 3) Can the family provide the appropriate care for the patient at home?; 4) Is it really better for the patient or just better for the surgeon?. If a surgeon embarks on a same day discharge program, rigorous selection criteria must be instituted and followed. In addition, the patient must have free choice with respect to a same day discharge versus a 24-hour stay

Objective. The purpose of this study was to evaluate the efficacy and safety of the drained-clamped method with intra-articular infusion of tranexamic acid (TA) for reducing blood loss in total knee arthroplasty (TKA). Material and Methods. From November 2011 to July 2014 inclusive, 72 patients with a diagnosis of osteoarthritis underwent unilateral primary TKA using a computed tomography (CT) free navigation system. Patients were randomly divided into two groups: group T (n=40) was given 2000 mg (40 ml) of TA and group W (n=32) was given 40 ml sterile saline only. All operations were performed under total anaesthesia through the medial mid-vastus approach. Cemented posterior stabilised or cruciate retaining prostheses were used. The patella was resurfaced. After tourniquet release and wound suture, TA or saline was infused into the knee joint in addition to the drained-clamped method for 2 hours. For VTE prophylaxis, all patients received bilateral intermittent pneumatic calf compressors, thromboembolic deterrent stockings, and subcutaneous injection of enoxaparin (4000IU daily). We evaluated the hematocrit, hemoglobin and the postoperative estimate of bleeding. At postoperative days 4, extremity venous ultrasonography was performed for the investigation of venous thromboembolism in the latest 40 patients and contrast-enhanced CT was performed in the latest 34 patients without a previous history of asthma and diminished renal function. The present study received institutional review board approval, and informed consent was obtained from all patients. Results. Group T had lower hematocrit and hemoglobin levels at postoperative day 1. Group T had higher hemoglobin levels at postoperative days 3 and 7, respectively. The postoperative estimate of bleeding in group T was 739.2 ± 318.9 ml on average, which was significantly less than group W which was 999.8 ± 414.1 ml (p <0.01). The rate of asymptomatic deep vein thrombosis and pulmonary embolism was 57.1% and 29.4% in group T, and 36.8% and 11.8% in group W, respectively. There were no significant differences between the two groups. Conclusion. The drain-clamped method with intra-articular infusion of TA was safe and effective for reducing the amount of blood loss in TKA, without increasing the risk of VTE

Background. Tranexamic acid (TXA) is a lysine analog that has been shown to reduce intra-operative blood loss in total joint replacements. Effect of TXA in morbid obese patients has not been established. The aim of this study was to evaluate the effect of TXA on change of haematocrit (HCT) and packed RBC (PRBC) blood transfusion rate in our institution, especially in morbid obese patients. Methods. Between January 2014 and December 2014, 216 primary and revision hip and knee arthroplasty were identified from our prospective institutional database. All cases were performed by two adult reconstruction specialists. All primary total hip arthroplasties (THA) were non-cemented and all primary total knee arthroplasties (TKA) were cemented with similar implant and technique. Use of TXA in our institution was initiated on August of 2014. TXA was given intravenously (IV) as one gram prior to incision and one gram at the time of femoral preparation in THA or cementation in TKA, not exceeding 10mg/kg. In cases where IV TXA was contraindicated, topical was used. We analyzed pre- and post-operative hematocrit and transfusion rate. Criteria for transfusion was HCT < 25 or Hb < 9. 72 patients (33%) were considered morbid obese with body mass index (BMI) ≥ 35. Results. In the non-TXA group, 50 out of 126 cases (40%) were transfused (17 THA, 25 TKA, 5 revision THA, 3 revision TKA), ranging from 1–5 PRBC. In the TXA group, 13 out of 90 cases (14%) were transfused (3 THA, 8 TKA, 2 revision THA), ranging 1–2 PRBC. This difference was statistically significant (p=0.0001). The overall drop in the TXA group HCT was 5.9 ± 3.9, as compared to 9.8 ± 4.3 in the non-TXA groups, which was statistically significant (p=0.0001). The mean pre- and post-operative HCT was 37.4 ± 4.3 and 28.2 ± 3 in the transfused patients without TXA. The average drop in HCT was 9.3 ± 4.3. The mean pre- and post-operative HCT was 34.3 ± 4.1 and 27.4 ± 1.9 in the transfused patients without TXA. The average drop in HCT was 7.3 ± 2.9. In the morbid obese patients, 45 did not receive TXA, 17 had transfusion with average drop in HCT of 9.6 ± 3.9; 29 received TXA and 2 had transfusion with average drop in HCT of 5.9 ± 3.1. There transfusion and drop in HCT was significantly less for morbid obese patients that received TXA (p=0.0001). Discussion and Conclusions. Since initiating TXA in our institution, the overall transfusion rate in both primary and revision arthroplasty cases have dramatically declined (26%). This was more evident in morbidly obese patients. In cases that needed transfusion with TXA, only one or two PRBC was given, which was a drastic improvement

We prospectively audited 79 patients undergoing primary knee or hip arthroplasty (38 knees, 41 hips) and found that 66% (58% of knees, 73% of hips) had at least one unit of blood transfused postoperatively, with a mean transfusion requirement of 1.3 units per patient (1.1 for knees, 0 to 6; 1.5 for hips, 0 to 4). We then established a new protocol for postoperative blood transfusion. This requires the calculation of the maximum allowable blood loss (MABL) that each individual patient can safely lose based upon their weight and preoperative haematocrit. The total blood loss up to this volume is replaced with colloid. When a patient’s total blood loss reaches their MABL their haematocrit is measured at the bedside using the Microspin system (Bayer plc, Newbury, UK). If their haematocrit is low (< 0.30 for men, < 0.27 for women), blood is transfused. As a safety net all patients have their haemoglobin formally checked on days 1, 2, and 3 after surgery and have a transfusion if the haemoglobin levels are less than 8.5 g/dl. We conducted a further audit of 82 patients (35 knees, 47 hips) after the introduction of this protocol. Under the new protocol only 24% of patients required blood (11% of knees, 34% of hips) with a mean transfusion requirement of 0.56 units per patient (0.26 for knees, 0 to 4; 0.79 for hips, 0 to 4). The use of clinical audit and the introduction of strict guidelines for transfusion can change transfusion practice and result in improved patient care. Our transfusion protocol is a simple and effective method of keeping transfusion to a minimum and is particularly useful in departments which do not have the facility to use autologous blood or reinfusion drains for elective orthopaedic surgery

Previous studies have indicated that prolonged surgical time may lead to higher rates of infection following total hip arthroplasty (THA). The purpose of this study was to evaluate the influence of surgical time on 30-day complications following THA and to determine if there was a time interval associated with worse outcomes. Patients ≥18 years who underwent THA between 2005 and 2016 were identified from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database using procedural codes. Patients with surgical durations >240 minutes were excluded. Patient demographics, operation length, and 30-day major and minor complications were ascertained. Multivariable regression was used to determine if the rate of complications differed depending on length of operation, while adjusting for relevant covariables, and to identify independent predictors of operation length. Covariables of interest included age, sex, American Society of Anaesthesiologists (ASA) class, smoking status, functional status, comorbidities, anesthesia type, and Body Mass Index (BMI). A total of 131,361 THA patients (average age 65 ±12 years) were identified from the database. Of these, 2,177 (1.64%) experienced a major complication, and 3,504 (2.64%) experienced a minor complication within 30-days of the initial procedure. Average operation length was 91.9 minutes (range 20 – 240 minutes). Independent predictors of prolonged operation length included overweight/obese BMI, male sex, cancer, dependent functional status, epidural anaesthetic, lower pre-operative hematocrit, and ASA class II, III or IV vs. I Alternatively, older age, current smoking, and spinal anaesthetic were associated with shorter surgical durations. Unadjusted rates of both major and minor complications were significantly higher for patients whose operation lengths were ≥ 120 minutes (P>0.001). Specifically, patients whose operations lasted ≥ 120 minutes had higher rates of septic shock, sepsis, pulmonary embolism (PE), deep vein thrombosis (DVT), urinary tract infection (UTI), renal insufficiency, surgical site infection(SSI) and wound disruption. After covariable adjustment, surgical durations of 90–119 minutes increased the risk of minor complications by 1.2 (95%Confidence interval [95%CI] 1.1–1.3), while surgical durations of 120–179 minutes increased the risk of major complications by 1.4 (95%CI 1.3 – 1.6), and minor complications by 1.4 (95%CI 1.2 – 1.5), and surgical durations ≥180 minutes increased the risk of major complications by 2.1 (95%CI 1.8 – 2.6), and minor complications by 1.9 (95%CI 1.6 – 2.3). There was no difference in the overall risk of complications for operation times lasting 20 – 39, 40 – 59, or 60 – 89 minutes (P>0.05). In terms of specific complications, operation length ≥90 minutes was determined to be an independent risk factor for deep and superficial incisional SSI, as well as wound disruption, while operation length ≥ 120 minutes was an independent risk factor for sepsis, UTI, and deep, non-incisional SSI and operation length ≥ 180 minutes was an independent risk factor for PE, DVT, and cardiac arrest (p < 0 .05). These data indicate that prolonged surgical durations may be an independent predictor of major and minor complications following THA. This suggests that quality improvements could be made to improve operating room efficiency and surgical times and therefore postoperative outcomes

Over 300,000 total hip arthroplasties (THA) are performed annually in the USA. Surgical Site Infections (SSI) are one of the most common complications and are associated with increased morbidity, mortality and cost. Risk factors for SSI include obesity, diabetes and smoking, but few studies have reported on the predictive value of pre-operative blood markers for SSI. The purpose of this study was to create a clinical prediction model for acute SSI (classified as either superficial, deep and overall) within 30 days of THA based on commonly ordered pre-operative lab markers and using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. All adult patients undergoing an elective unilateral THA for osteoarthritis from 2011–2016 were identified from the NSQIP database using Current Procedural Terminology (CPT) codes. Patients with active or chronic, local or systemic infection/sepsis or disseminated cancer were excluded. Multivariate logistic regression was used to determine coefficients, with manual stepwise reduction. Receiver Operating Characteristic (ROC) curves were also graphed. The SSI prediction model included the following covariates: body mass index (BMI) and sex, comorbidities such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), smoking, current/previous steroid use, as well as pre-operative blood markers, albumin, alkaline phosphate, blood urea nitrogen (BUN), creatinine, hematocrit, international normalized ratio (INR), platelets, prothrombin time (PT), sodium and white blood cell (WBC) levels. Since the data met logistic assumption requirements, bootstrap estimation was used to measure internal validity. The area under the ROC curve for final derivations along with McFadden's R-squared were utilized to compare prediction models. A total of 130,619 patients were included with the median age of patients at time of THA was 67 years (mean=66.6+11.6 years) with 44.8% (n=58,757) being male. A total of 1,561 (1.20%) patients had a superficial or deep SSI (overall SSI). Of all SSI, 45.1% (n=704) had a deep SSI and 55.4% (n=865) had a superficial SSI. The incidence of SSI occurring annually decreased from 1.44% in 2011 to 1.16% in 2016. Area under the ROC curve for the SSI prediction model was 0.79 and 0.78 for deep and superficial SSI, respectively and 0.71 for overall SSI. CHF had the largest effect size (Odds Ratio(OR)=2.88, 95% Confidence Interval (95%CI): 1.56 – 5.32) for overall SSI risk. Albumin (OR=0.44, 95% CI: 0.37 – 0.52, OR=0.31, 95% CI: 0.25 – 0.39, OR=0.48, 95% CI: 0.41 – 0.58) and sodium (OR=0.95, 95% CI: 0.93 – 0.97, OR=0.94, 95% CI: 0.91 – 0.97, OR=0.95, 95% CI: 0.93 – 0.98) levels were consistently significant in all clinical prediction models for superficial, deep and overall SSI, respectively. In terms of pre-operative blood markers, hypoalbuminemia and hyponatremia are both significant risk factors for superficial, deep and overall SSI. In this large NSQIP database study, we were able to create an SSI prediction model and identify risk factors for predicting acute superficial, deep and overall SSI after THA. To our knowledge, this is the first clinical model whereby pre-operative hyponatremia (in addition to hypoalbuminemia) levels have been predictive of SSI after THA. Although the model remains without external validation, it is a vital starting point for developing a risk prediction model for SSI and can help physicians mitigate risk factors for acute SSI post THA

Total knee arthroplasty (TKA) is the most commonly performed elective orthopaedic procedure. With an increasingly aging population, the number of TKAs performed is expected to be ∼2,900 per 100,000 by 2050. Surgical Site Infections (SSI) after TKA can have significant morbidity and mortality. The purpose of this study was to construct a risk prediction model for acute SSI (classified as either superficial, deep and overall) within 30 days of a TKA based on commonly ordered pre-operative blood markers and using audited administrative data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. All adult patients undergoing an elective unilateral TKA for osteoarthritis from 2011–2016 were identified from the NSQIP database using Current Procedural Terminology (CPT) codes. Patients with active or chronic, local or systemic infection/sepsis or disseminated cancer were excluded. Multivariate logistic regression was conducted to estimate coefficients, with manual stepwise reduction to construct models. Bootstrap estimation was administered to measure internal validity. The SSI prediction model included the following co-variates: body mass index (BMI) and sex, comorbidities such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), smoking, current/previous steroid use, as well as pre-operative blood markers, albumin, alkaline phosphatase, blood urea nitrogen (BUN), creatinine, hematocrit, international normalized ratio (INR), platelets, prothrombin time (PT), sodium and white blood cell (WBC) levels. To compare clinical models, areas under the receiver operating characteristic (ROC) curves and McFadden's R-squared values were reported. The total number of patients undergoing TKA were 210,524 with a median age of 67 years (mean age of 66.6 + 9.6 years) and the majority being females (61.9%, N=130,314). A total of 1,674 patients (0.8%) had a SSI within 30 days of the index TKA, of which N=546 patients (33.2%) had a deep SSI and N=1,128 patients (67.4%) had a superficial SSI. The annual incidence rate of overall SSI decreased from 1.60% in 2011 to 0.68% in 2016. The final risk prediction model for SSI contained, smoking (OR=1.69, 95% CI: 1.31 – 2.18), previous/current steroid use (OR=1.66, 95% CI: 1.23 – 2.23), as well as the pre-operative lab markers, albumin (OR=0.46, 95% CI: 0.37 – 0.56), blood urea nitrogen (BUN, OR=1.01, 95% CI: 1 – 1.02), international normalized ratio (INR, OR=1.22, 95% CI:1.05 – 1.41), and sodium levels (OR=0.94, 95% CI: 0.91 – 0.98;). Area under the ROC curve for the final model of overall SSI was 0.64. Models for deep and superficial SSI had ROC areas of 0.68 and 0.63, respectively. Albumin (OR=0.46, 95% CI: 0.37 – 0.56, OR=0.33, 95% CI: 0.27 – 0.40, OR=0.75, 95% CI: 0.59 – 0.95) and sodium levels (OR=0.94, 95% CI: 0.91 – 0.98, OR=0.96, 95% CI: 0.93 – 0.99, OR=0.97, 95% CI: 0.96 – 0.99) levels were consistently significant in all prediction models for superficial, deep and overall SSI, respectively. Overall, hypoalbuminemia and hyponatremia are both significant risk factors for superficial, deep and overall SSI. To our knowledge, this is the first prediction model for acute SSI post TKA whereby hyponatremia (and hypoalbuminemia) are predictive of SSI. This prediction model can help fill an important gap for predicting risk factors for SSI after TKA and can help physicians better optimize patients prior to TKA

Introduction. Total knee arthroplasty (TKA) is associated with significant blood loss, for which blood transfusion might be necessary. The role of the tourniquet is controversial, though it is widely used by orthopedic surgeons. Its use was believed to be effective in decreasing intraoperative blood loss and creating a bloodless surgical field, which theoretically would facilitate the cementing technique and other surgical procedures. However, reactive blood flow reached its peak within five minutes after the tourniquet had been released. The tourniquet controls intraoperative blood loss, but cannot stop postoperative blood loss. Patients who were managed with a tourniquet during the operation often complained of thigh pain. This was possibly caused by the direct pressure of an inflated tourniquet on the nerves and local soft tissues. Limb swelling and increased soft tissue tension caused by reactive hyperperfusion after tourniquet deflation may also contribute to the wound pain. The aim of our study is to investigate the effect of tourniquet on blood loss and soft tissue damage in TKA. Materials & Methods. In this prospective, randomized study, 72 patients with primary cemented knee arthroplasty were randomly allocated to two groups (with and without tourniquet). The operation time, blood loss, post-operative hemoglobin, hematocrit, markers of soft tissue damage (myoglobin, Cretine Posphokinase(CK), LDH, GOT, Creatinine), status of rehabilitation, knee pain and thigh pain were monitored until discharge. Results. The intra-operative and total blood loss is more in non-tourniquet. The post-operative levels of hemoglobin and hematocrit were significant higher in tourniquet group until postoperative day 4. Using tourniquet also shortened the operation time. Patients managed without tourniquet showed higher CK level in postoperative day 2. The severity of knee pain was similar in both group. Mild thigh pain was noted in tourniquet group. Conclusions. Our randomized controlled trial revealed that the usage od tourniquet in TKA may save blood and save time with minor adverse effect. Without using tourniquet, the prolonged surgical time and excessive hemostasis may cause more soft tissue damage

Introduction. Total joint arthroplasty is associated with substantial blood loss as well as changes in basic metabolic labs. Routinely patients receive multiple post-operative blood draws for measuring hematocrit, hemoglobin (H&H), and basic metabolic panels (BMP). Based on a multimodal approach to blood conservation and pre-operative optimization, we questioned the need to check daily labs on our inpatient primary total hip and knee patients. The purpose of this study was to identify risk factors for transfusion and metabolic abnormalities requiring treatment in an attempt to reduce the number of post-operative blood draws and labs. Methods. We retrospectively reviewed all 1134 patients who underwent primary total hip (THA) or total knee arthroplasty (TKA) from July 2016 to March 2017 in our inpatient hospital setting. There were 733 TKA and 401 THA. Pre- and post-operative lab values were reviewed and correlated with transfusion and medical treatments. Results. Twelve patients received a post-operative transfusion (1.1%). In TKA patients 2 of 733 (0.2%) were transfused while in THA patients 10 of 401 (2.4%) were transfused. Of the 12 patients receiving transfusions 11 were females, and in all 12 the pre-operative hemoglobin was less than 13. For the overall series of 1134 patients, 176 (15.5%) required potassium chloride supplementation based on BMP. Only patients with pre-existing renal disease or diuretic treatment received potassium chloride supplementation. Conclusions. Based on our findings, only patients with pre-operative hemoglobin less than 13 require post-operative H&H. Additionally, only patients with low pre-operative potassium, history of renal disease, or active treatment with a diuretic require post-operative BMP

The purpose of this prospective randomized study was to compare the visible, hidden, total blood loss and postoperative haemodynamic change of subcutaneous and intra-articular indwelling closed suction drainage method after total knee arthroplasty (TKA). Patients with primary osteoarthritis, who underwent unilateral TKA were enrolled; Group A with subcutaneous (n=78) and group B with intra-articular (n=79) indwelling closed suction drainage method. Total blood loss, visible blood loss, internal blood loss, postop (day 1), 5. th. , 10. th. day hemoglobin, hematocrit levels were compared. Allogenic blood transfusion rate and complications related to soft tissue hematoma formation were additionally compared. Subcutaneous indwelling closed suction drainage method reduced both the visible blood loss and total blood loss (hemovac drainage + internal blood loss) thus decreasing the rate of allogenic transfusion. Although the minor complications such as the incidence of bullae formation and the ecchymosis were higher in the subcutaneous indwelling group, the functional outcome at postoperative 2 year did not demonstrate difference from intra-articular drainage group

Introduction. Peri-operative hyperglycemia has many etiologies, including medication, impaired glucose tolerance, uncontrolled diabetes mellitus (DM), or stress, the latter of which is common in post-surgical patients. Our study aims were to investigate if post-operative day 1 (POD1) blood glucose level was associated with post-operative complications after total joint arthroplasty (TJA), including periprosthetic joint infection (PJI), and to determine a threshold for glycemic control that surgeons should strive for during a patient's hospital stay. Methods. A single-institution retrospective review was conducted on 24,857 primary TJAs performed from 2001–2015. Of these, 13,198 had a minimum one-year follow-up (mean 5.9 years). Demographics, Elixhauser comorbidities, laboratory values, complications and readmissions were collected. POD1 morning blood glucose levels were utilised and correlated with PJI, as defined by the Musculoskeletal Infection Society criteria. The mean age and body mass index of the population was 63.4 years and 30.2 kg/m2, respectively; the sample was comprised of 56.6% females and 48.4% knees. Multivariate analysis was used to determine the influence of several important covariates on complication rate. Youden's J statistic was utilised to determine an optimal blood glucose threshold. An alpha level of 0.05 was used to determine statistical significance. Results. The rate of PJI significantly increased linearly from blood glucose levels of 115 mg/dL and higher. When examining only patients with a minimum of one-year follow-up, the logistic regression demonstrated that blood glucose levels (odds ratio 1.004 per increment, 95% confidence interval: 1.002–1.006, p=0.001) were a significant risk factor for development of PJI by 1.004 per 1 mg/dL increment. For instance, a patient that had a post-operative glucose level of 280 mg/dL compared to a patient with a blood glucose level of 100 mg/dL had a 2.05 increased odds of developing PJI. The Youden index was used to determine an optimal blood glucose threshold of 137 mg/dL to reduce the likelihood of PJI at one year. Multivariate analysis revealed that blood glucose levels (OR 1.004, p=0.001), male gender (OR 1.480, p=0.001), body mass index (OR 1.049, p<0.001), operative time (OR 1.004, p=0.006), length of stay (OR 1.059, p<0.001), post-operative hematocrit (OR 0.751, p=0.003), peripheral vascular disease (OR 1.942, p=0.037), liver disease (OR 2.576, p=0.004), rheumatic disease (OR 1.991, p=0.003), and alcohol abuse (OR 2.588, p=0.030) were associated with PJI. Operative or hospital factors that were associated with PJI included the following: low post-operative hemoglobin (OR 0.766 per increment, 95% CI: 0.599–0.979, p=0.034) and longer length of stay (OR 1.145 per day, 95% CI: 1.104–1.187, p<0.001). The PJI rate in the entire cohort was 1.59% (1.46% in non-diabetics vs. 2.39% in diabetics, p=0.001). There was no association between blood glucose level and PJI (OR 1.002, 95% CI: 0.998–1.006, p=0.331) in diabetic patients, although there was a linear trend for post-operative blood glucose predicting PJI. Discussion. The relationship between POD1 blood glucose levels and PJI increased linearly, with an optimal cut off of 137 mg/dL. Immediate and strict post-operative glycemic control may be critical in reducing post-operative complications, and even mild hyperglycemia was significantly associated with PJI

Background. While tranexamic acid (TXA) has been well shown to reduce blood loss after joint replacement surgery, little is known regarding its effectiveness in obese patients. The aim of this study was to evaluate the effect of TXA on packed red blood cell (PRBC) blood transfusion rates and change in hemoglobin (HGB) and hematocrit (HCT) for obese patients undergoing joint replacement at our institution. Material and methods. Between January and December 2014, 117 consecutive primary joint replacements (THA n=23; TKA n=94) were performed in obese patients (BMI ≥ 30kg/m. 2. ) by two surgeons. Medical records were reviewed and identified that TXA was utilized in 45 (38.5%) arthroplasties. TXA was given intravenously (IV) in two doses: (1) one gram prior to incision and (2) one gram at the time of femoral preparation in THA or prior to cementation in TKA. Topical TXA was utilized in cases where IV TXA was contraindicated. PRBC transfusion rates, changes in HBG and HCT, and occurrence of thrombolytic events were recorded from hospital records. Results. There was no difference in the mean BMI between the group that received TXA and those that did not (36.3±4.6 kg/m. 2. vs. 37.8±6.6kg/m. 2. ; p=0.184). The mean operative time for the TXA group (110.1±42.1 min)was significantly longer than group that did not receive TXA (94.5±32.2 min) (p<0.026). Both the incidence (11.1% vs. 34.7%) and total number (7 vs. 51) of PRBC blood transfusions were significantly reduced with TXA use (p=0.005). The change in HBG (2.7 ± 1.3 g/dl vs. 3.6 ±1.3 g/dl) and the change in HCT (4.5±3.5% vs. 9.7±4.6%) were significantly reduced in the group that received TXA (p<0.001and p<0.001, respectively). Two pulmonary emboli were reported in the group that did not receive TXA, whereas no thrombolytic events were reported in the group that did receive TXA. Conclusion. The use of TXA in obese patients undergoing total joint arthroplasty significantly reduced the number of PRBC blood transfusions, change in HGB and HCT and was not associated with any thrombolytic events

The transgluteal approach (TG) offers a user-friendly alternative to the heavily promoted anterior approach (DA) to total hip arthroplasty (THA). Our purpose is to illustrate the advantages and details of the technique, illustrate the surgical anatomy that differentiates TG from the “traditional posterior” technique, and point out the surprising similarities to the DA. Unlike the traditional posterior THA, the TG preserves ITB, quadratus, and obturator externus. The conjoined tendon is released, providing direct access to the femur via the piriformis fossa. Direct acetabular access is facilitated either by using a portal through which reaming and cup impaction are performed or offset instrumentation. Intra-operative digital radiography was used in all cases. We present the clinical and radiographic outcome of 850 consecutive primary THA using the TG. At 2–6 years follow-up, dislocation rate was 0.3%, cup abduction 35–50 degrees in 97%, 92% used a cane within 5 days, 61% reported driving within the first post-operative week. No intra-operative trochanteric fractures, nerve injuries, or wound problems were observed. Three calcar fractures were wired. Hospital stay averaged 1.5 days, no patient received a blood transfusion if their pre-operative hematocrit was normal, and 88% of patients were discharged on acetaminophen only. The TG is a reliable and highly successful alternative to commonly used soft tissue sparing approaches in THA. It permits accelerated recovery while assuring optimal component orientation. The surgeon familiar with the traditional posterior approach can embark on a gradual learning curve that can minimise the complication rate as the surgeon learns the technique

Hemorrhage and transfusion requirements in spine surgery are common. This is especially true for thoracic and lumbar fusion surgeries. The purpose of this papersi to determine predictive factors for transfusion and their effect on short-term post-operative outcomes for thoracic and lumbar fusions. The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was used to identify patients that underwent lumbar or thoracic fusion surgery from 2010 to 2013. Univariate and multivariate regression analysis was used to determine predictive factors and post-operative complications associated with transfusion. A total of 14,249 patients were included in this study; 13,586 had lumbar fusion and 663 had thoracic fusion surgery. The prevalence of transfusion was 35% for thoracic fusion and 17.5% for lumbar fusion. The multivariate analysis showed that age between 50–60 (OR 1.38, CI: 1.23–1.54), age between 61–70 (OR 1.65, CI: 1.40–1.95), dyspnea (OR 1.11, CI: 1.02–1.23), hypertension (OR 1.14, CI: 1.02–1.27), ASA class (OR 1.73, 1.18–1.45), pre-operative blood transfusion (OR 1.91, CI: 1.04–3.49), and extended surgical time (OR 4.51, CI: 4.09–4.98) were predictors of blood transfusion requirements for lumbar fusion. While only pre-operative BUN (OR 1.04, CI: 1.01–1.06) and extended surgical time (OR 4.70, CI: 3.12–6.96) were predictors of transfusion for thoracic fusion. In contrast, higher pre-operative hematocrit was protective against transfusion. Patients transfused who underwent lumbar fusion had an increased risk to develop superficial wound infection, deep wound infection, venous thromboembolism, myocardial infarction and had longer length of hospital stay. Patients transfused who underwent thoracic fusion were more likely to have venous thromboembolism and extended length of hospital stay. However, mortality was not associated with blood transfusion. This study used a large database to characterise the incidence, predictors and post-operative complications associated with blood transfusion in thoracic and lumbar fusion surgeries. Pre- and post-operative planning for patients deemed to be at high-risk of requiring blood transfusion should be considered to reduce post-operative complication in this population

Acute peri-operative blood loss warranting transfusion is a frequent consequence of major joint replacement (TJR) surgery. Significant peri-operative anemia can contribute to hypotension, dyspnea, coronary ischemia and other peri-operative medical events that can result in increased risk of peri-operative complications, readmissions and impair the patient's ability to mobilise after surgery resulting in a longer length of stay (LOS) and increase skilled nursing facility (SNF) utilization. The risks associated with allogeneic blood transfusions (ABT) administered to treat symptomatic peri-operative anemia are numerous and extend beyond the concerns of transmission of communicable disease (HIV, hepatitis, other). Patients receiving ABTs have been shown to have a longer hospital LOS, higher risk of infection, and higher mortality after TJR than those who do not require transfusion after surgery. As a result, many different pre-operative, peri-operative and post-operative strategies have been utilised to minimise peri-operative blood loss and transfusion need for patients undergoing TJR. Several studies have shown that the strongest predictor of the need for ABT in the TJR patient is the pre-operative hematocrit (Hct). As a result, all patients with unexplained pre-operative anemia should be evaluated for an underlying cause prior to elective TJR surgery. In recent years, focus has shifted towards peri-operative reduction of blood loss with the use of pharmacologic agents like tranexamic acid (TXA). These agents work by inhibiting fibrinolysis and activating plasminogen. Numerous studies have shown that TXA given IV, applied topically into the surgical wound or given orally have been shown to reduce peri-operative bleeding and ABT after both THA and TKR. Regardless of route of administration, all appear to be more efficacious and considerably more cost-effective in reducing the need for ABT than other methods discussed previously. Despite concerns about the potential increased thromboembolic risk in patients undergoing TJR, there does not appear to be any conclusive evidence suggesting an increased risk of venous thromboembolic disease (VTED) in TJR patients who receive peri-operative TXA. Although it may be unnecessary, many TJR surgeons still, however, avoid use of TXA in patients with a past history of VTED, stroke, coronary artery disease (including coronary stents), renal insufficiency, hypercoagulable state and seizure disorder. The use of topical TXA may be safer in some of these high risk patients since systemic absorption is minimal when administered via this route. Although the optimal method of administration (IV, topical, oral or combined) has not yet been determined based on safety, cost and reduction of need for ABT, incorporation of tranexamic acid into a blood conservation program is clearly the standard of care for all TJR programs that should nearly eliminate the need for ABT for patients undergoing TJR

The effect of early surgery on hip fracture outcomes has received considerable study and although it has been suggested that early surgical treatment of these fractures leads to better patient outcomes, the findings are inconclusive. The American College of Surgeon's (ACS) National Surgical Quality Improvement Project (NSQIP) prospectively collects blinded, risk-adjusted patient-level data on surgical patients in over 600 participating hospitals worldwide. The primary objective of this study was to determine the proportion of ACS-NSQIP hospital patients that are currently being treated within the UK's National Institute for Health and Care Excellence (NICE) time to hip fracture surgery benchmark. The secondary objectives were to identify risk factors for missing the benchmark, and determine if the benchmark is associated with improved 30-day patient outcomes. Patients that underwent hip fracture surgery between 2005–2013 and entered in the ACS-NSQIP database were included in the study. Counts and proportions were used to determine how frequently the NICE benchmark was met. Multivariate regression analysis was used to identify significant predictors of missing the NICE benchmark and determine if missing the benchmark was associated with 30-day mortality/complications rates. 26,006 patients met the study enrolment criteria. 71.4% of patients were treated within the NICE benchmark and 89.4% were treated by post-admission day two. Gender, dyspnea, infectious illness, bleeding disorders, preoperative hematocrit, preoperative platelet count, arthroplasty procedure type, race other than White, and hip fracture diagnosis were all statistically significant predictors of missing the benchmark (p<0.01). Meeting the NICE benchmark was not associated with reductions in major complications (OR=0.93, CI=0.83–1.05, p=0.23), nor a clinically significant difference in postoperative length of stay (LOS) (parameter estimate=0.77, p<0.01); however, it was associated with a decreased 30-day mortality (OR=0.88, CI=0.78–0.99, p=0.03) and the likelihood of minor complications (OR=0.92, CI=0.84–0.995, p=0.04). ACS-NSQIP hospitals are currently compatible with the NICE benchmark. However, data from the ACS-NSQIP database suggests that surgical treatment within the NICE benchmark may be unnecessarily narrow. Extending the benchmark to post-operative day two did not significantly increase the risk of 30-day mortality and minor complications; nor did it extend the average LOS. Neither the NICE benchmark, nor the extended two-day standard, was associated with reductions in major complications. The findings highlight the importance of further prospective investigation to monitor the effect of time to surgery benchmarks

Aim. Perioperative hyperglycemia has many etiologies including medication, impaired glucose tolerance, uncontrolled diabetes mellitus (DM), or stress, the latter of which is common to post-surgical patients. This acute hyperglycemia may impair the ability of the host to combat infection. 1. Our study aims to investigate if post-operative day 1 (POD1) blood glucose level is associated with complications, including periprosthetic joint infection (PJI), after total joint arthroplasty (TJA) and to determine a threshold for glycemic control that surgeons should strive for during a patient's hospital stay. Method. A single-institution retrospective review was conducted on 24,857 primary TJAs performed from 2001–2015. Demographics, Elixhauser comorbidities, laboratory values, complications and readmissions were collected. POD1 morning blood glucose levels were utilized and correlated with PJI, as defined by the Musculoskeletal Infection Society criteria. The Wald test was used to determine the influence of covariates on complication rate. An alpha level of 0.05 was used to determine statistical significance. Results. The rate of PJI significantly increased linearly from blood glucose levels of 115 mg/dL onwards. We determined that blood glucose (OR 1.004, 95% CI: 1.001–1.006, p=0.001), male gender (OR 1.480, 95% CI: 1.185–1.848, p=0.001), body mass index (OR 1.049, 95% CI: 1.033–1.065, p<0.001), operative time (OR 1.004, 95% CI: 1.001–1.007, p=0.006), length of stay (OR 1.059, 95% CI: 1.038–1.080, p<0.001), post-operative hematocrit (OR 0.751, 95% ci: 0.621–0.909, p=0.003), peripheral vascular disease (OR 1.942, 95% CI: 1.042–3.617, p=0.037), liver disease (OR 2.576, 95% CI: 1.344–4.935, p=0.004), rheumatic disease (OR 1.991, 95% CI: 1.266–3.132, p=0.003), and alcohol abuse (OR 2.588, 95% CI: 1.096–6.110, p=0.030) were associated with PJI. The Youden index was used to determine an optimal blood glucose threshold of 132 mg/dL to reduce the likelihood of PJI. The PJI rate in the entire cohort was 1.59% (1.46% in non-diabetics compared to 2.39% in diabetics, p=0.001). Diabetics did not have an association between blood glucose level and PJI (OR 1.002, 95% CI: 0.998–1.006, p=0.331), although there was a linear trend for postoperative glucose predicting PJI. Conclusions. The relationship between POD1 blood glucose levels and PJI increased linearly, with an optimal cut off of 132 mg/dL. Immediate and strict post-operative glycemic control is critical in reducing post-operative complications, and we demonstrate that even mild hyperglycemia is significantly associated with PJI